{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034159","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.620426+00:00","generated_at":"2026-06-04T11:34:48.519983+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Trevi Therapeutics reports FY2023 net loss $29.1M; cash $83M; trial timelines reaffirmed","bullets":["Net loss Q4 2023 $7.8M vs $5.5M in Q4 2022; FY2023 net loss $29.1M vs $29.2M in FY2022.","Cash, cash equivalents and marketable securities $83.0M at year-end 2023; expected runway into 2026.","Phase 2a RIVER trial for RCC topline data expected H2 2024; enrollment continuing across multiple sites.","Phase 2b CORAL trial for chronic cough in IPF topline expected H1 2025; SSRE expected H2 2024.","Human Abuse Potential study over 50% enrolled; topline data expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034159","json":"https://secwatch.observer/filing/0000950170-24-034159.json","markdown":"https://secwatch.observer/filing/0000950170-24-034159.md","text":"https://secwatch.observer/filing/0000950170-24-034159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024034159/0000950170-24-034159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024034159/trvi-20240320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:34:48.519983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"58305bd92bda6357190461307ecf6a88c3e1762e","claim":"Trevi Therapeutics, Inc. reported quarter and year ended December 31, 2023 results: net income Net loss: For the fourth quarter of 2023, the Company reported a net loss of $7.8 million, compared to a net loss of $5.. Guidance reaffirmed.","evidence_excerpt":"Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024034159/0000950170-24-034159-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2023"},{"label":"Net income","value":"Net loss: For the fourth quarter of 2023, the Company reported a net loss of $7.8 million, compared to a net loss of $5."},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}